Director Khan Bilal Arshad bought 135,000 shares ($2,160,000) on Feb 9 at $16.00; post-transaction holdings 251,427 shares (+116.0%)
Khan Bilal Arshad, a Director at SpyGlass Pharma, executed two separate purchases totaling 135,000 shares for $2,160,000.00 on 2026-02-09, just four trading days after the company's IPO. This represents a 116.0% increase to his prior shareholding of 116,427 shares, bringing his post-transaction position to 251,427 shares. The transaction occurred at $16.00, the offer price in SpyGlass's recent listing. Notably, this purchase is part of a broader cluster pattern: 14 other insiders also acquired shares within the past 14 days, suggesting coordinated accumulation among the leadership cohort following the IPO. For a newly public company still in early price discovery, insider participation in this magnitude and frequency merits close investor scrutiny regarding the board's conviction in the business at its public valuation.